schizandrin b has been researched along with fenofibrate in 4 studies
| Studies (schizandrin b) | Trials (schizandrin b) | Recent Studies (post-2010) (schizandrin b) | Studies (fenofibrate) | Trials (fenofibrate) | Recent Studies (post-2010) (fenofibrate) |
|---|---|---|---|---|---|
| 321 | 1 | 218 | 3,058 | 529 | 1,354 |
| Protein | Taxonomy | schizandrin b (IC50) | fenofibrate (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 2.371 | |
| Adenosine receptor A3 | Homo sapiens (human) | 5.701 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 5.701 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.118 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 2.371 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 5.701 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 8.633 | |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | 1 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 5.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, H; Han, YF; Ko, KM; Li, WY; Pan, SY; Zhao, XY | 1 |
| Dong, H; Fang, HY; Fong, WF; Ko, KM; Pan, SY; Xiang, CJ; Yu, ZL; Zhao, XY | 1 |
| Dong, H; Fong, WF; Guo, BF; Han, YF; Ko, KM; Pan, SY; Yu, ZL; Zhang, Y | 1 |
| Jia, ZH; Ko, KM; Pan, SY; Sun, N; Wang, XY; Yu, Q; Yu, ZL; Zhang, Y; Zhu, PL | 1 |
4 other study(ies) available for schizandrin b and fenofibrate
| Article | Year |
|---|---|
A novel experimental model of acute hypertriglyceridemia induced by schisandrin B.
Topics: Animals; Cyclooctanes; Disease Models, Animal; Fenofibrate; Hypertriglyceridemia; Hypolipidemic Agents; Lignans; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Polycyclic Compounds | 2006 |
Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice.
Topics: Animals; Bile Acids and Salts; Cholesterol; Cholesterol, Dietary; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Fenofibrate; Hypercholesterolemia; Hypolipidemic Agents; Lignans; Liver; Male; Mice; Mice, Inbred ICR; Polycyclic Compounds; Schisandra; Triglycerides | 2008 |
Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate.
Topics: Animals; Cholesterol; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Fenofibrate; Hypertriglyceridemia; Hypolipidemic Agents; Lignans; Liver; Male; Mice; Mice, Inbred ICR; Polycyclic Compounds; Schisandra; Triglycerides | 2011 |
Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholesterol; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Fenofibrate; Hyperlipidemias; Lignans; Lipoproteins; Male; Mice; Mice, Inbred ICR; Polycyclic Compounds; Time Factors; Triglycerides | 2013 |